

Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT

Andrée-Laure Herr,¹ Nabil Kabbara,¹ Carmem M. S. Bonfim,² Pierre Teira,¹ Franco Locatelli,³ Karin Tiedemann,⁴ Arjan Lankester,⁵ Jean-Pierre Jouet,⁶ Chiara Messina,⁷ Yves Bertrand,⁸ Cristina Díaz de Heredia,⁹ Christina Peters,¹⁰ Wagnara Chaves,¹ Samir K. Nabhan,² Irina Ionescu,¹ Eliane Gluckman,¹ and Vanderson Rocha¹

¹Eurocord, Hôpital Saint-Louis, Paris, France; ²Hospital de Clinicas, Curitiba, Brazil; ³IRCCS Ospedale Bambino Gesù, Rome, University of Pavia, Pavia, Italy; ⁴Royal Children's Hospital, Melbourne, Australia; ⁵Leiden University Medical Center, Leiden, The Netherlands; ⁶Hôpital Claude Huriez, Lille, France; ⁷Clinica di Oncematologia Pediatrica, Padova, Italy; ⁸IHOP-Hôpital Debrousse, Lyon, France; ⁹Hospital Vall d'Hebron, Barcelona, Spain; and ¹⁰Paediatric Diseases Working Party-EBMT, St-Anna Kinderspital, Vienna, Austria

We analyzed risk factors influencing outcomes after related (R) human leukocyte antigen-identical cord blood transplantation (CBT) for 147 patients with malignancies reported to Eurocord-European Group for Blood and Marrow Transplantation. CBT has been performed since 1990; median follow-up was 6.7 years. Median patient age was 5 years. Acute leukemia was the most frequent diagnosis (74%). At CBT, 40 patients had early, 70 intermediate, and 37

advanced disease. CB grafts contained a median of 4.1×10^7 /kg total nucleated cells (TNCs) after thawing. The cumulative incidence (CI) of neutrophil recovery was 90% at day +60. CIs of acute and chronic graft-versus-host disease (GVHD) were 12% and 10% at 2 years, respectively. At 5 years, CIs of nonrelapse mortality and relapse were 9% and 47%, respectively; the probability of disease-free survival (DFS) and overall survival were 44% and 55%, respectively.

Among other factors, higher TNCs infused was associated with rapid neutrophil recovery and improved DFS. The use of methotrexate as GVHD prophylaxis decreased the CI of engraftment. Patients without advanced disease had improved DFS. These results support banking and use of CB units for RCBT. Cell dose, GVHD prophylaxis not including methotrexate, and disease status are important factors for outcomes after RCBT. (*Blood*. 2010;116(11):1849-1856)

Introduction

Since the publication of the first related (R) cord blood transplantation (CBT) in a child with Fanconi anemia,¹ umbilical cord blood (CB) has been well recognized and widely used as a source of hematopoietic stem cells for the treatment of both nonmalignant and malignant disorders in pediatric and adult patients. In children, despite a decreased incidence of neutrophil recovery after related human leukocyte antigen (HLA)-identical CBT compared with bone marrow transplantation (BMT), survival according to disease type after CBT (malignant or nonmalignant diseases) has been shown to be comparable with that after BMT.² Moreover, incidences of acute and chronic graft-versus-host disease (GVHD) were decreased after CBT compared with BMT.² However, follow-up was short (2 years) in this analysis, and long-term outcomes were not described.² RCBT in hemoglobinopathies, namely sickle cell disease and thalassemia, result in relatively low toxicity, particularly when methotrexate (MTX) is not used for GVHD prophylaxis.³

Few studies have reported outcomes after RCBT for patients with malignant disorders.^{2,4-6} A Eurocord study reported risk factors for outcomes in 102 children with acute leukemia (AL) who received a CB transplant from either a related donor (n = 42; 12 with HLA-mismatched donor and 30 with HLA-identical donor) or unrelated donor (n = 60); in that study, better disease-free survival (DFS) was reported in patients who received a transplant

in first or second complete remission.⁵ In a subsequent preliminary analysis, we showed that outcomes after HLA-identical RCBT were better than after HLA-mismatched RCBT in patients with malignancies.⁷ In the present study, we analyzed risk factors for outcomes solely after related HLA-identical CBT in malignancies and describe long-term outcomes, particularly relapse. There were 147 patients who underwent RCBT and reported to Eurocord-European Group for Blood and Marrow Transplantation (EBMT) with complete data over the past 2 decades, of whom 45 patients were included in previous studies.^{2,4,5}

Methods

Data collection

Data on patient, disease, CB unit characteristics, and outcomes of RCBT performed from October 26, 1990, to September 22, 2008, were collected with the use of the standardized Eurocord CBT questionnaire (100-day report and yearly follow-up forms). Data were entered in the Eurocord database after validation by clinical research physicians. For the purposes of this study, each transplantation center was contacted individually for participation in this study. They were asked to complete missing data and to update patient follow-up. Approval was given by all participating transplantation centers for this study. According to EBMT rules, patients gave

Submitted February 25, 2010; accepted May 27, 2010. Prepublished online as *Blood* First Edition paper, June 10, 2010; DOI 10.1182/blood-2010-02-271692.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2010 by The American Society of Hematology

informed consent for data entry into the EBMT and Eurocord registry databases in accordance with the Declaration of Helsinki.

Patient selection and follow-up

Among CBTs performed until December 31, 2008, and reported to the Eurocord or EBMT registries, we selected patients with a diagnosis of malignant disease who had a first allogeneic single HLA-identical (HLA-A, -B and -DRB1 antigenic typing) unmanipulated CBT from a related donor. One hundred sixty-two cases fulfilled inclusion criteria, and 15 cases were excluded due to lack of response from the transplantation centers to participate in this study. We thus included 147 cases with sufficient patient, disease, CB characteristics, and posttransplantation outcomes (minimum follow-up of 100 days after CBT) in this analysis. CBT was performed over a period of 18 years, from 1990 to 2008 (median year of transplantation being 2000), in 67 different transplantation centers (each reporting between 1 and 13 cases) and 25 different countries worldwide (excluding the United States and Japan), including 112 CBTs performed in European countries. Median follow-up was 6.7 years, ranging from 7 months to 18 years (only 3 patients having a follow-up < 1 year). Of 83 live patients, follow-up was updated to 2009 for 59 patients, to 2008 for 10 patients, and to previous years for 14 patients.

Definitions

Disease status was classified according to criteria from the Center for International Blood and Marrow Transplant Research.⁸ Early disease included cases of AL in first complete remission (CR), lymphomas in first CR, and chronic myeloid leukemia (CML) in first chronic phase. Intermediate disease included cases of AL in at least second CR, lymphomas in at least second CR, or CML in accelerated phase. Advanced disease included AL not in CR (refractory), lymphomas not in CR, CML in blastic crisis or at least second chronic phase, all myelodysplastic disorders, and solid tumors.

A myeloablative conditioning was defined as a regimen containing either total body irradiation (TBI) with a dose of more than 6 Gy, a dose of oral busulfan of more than 8 mg/kg, a dose of intravenous busulfan of more than 6.4 mg/kg, or a dose of treosulfan of at least 12 g/m². Any other conditioning regimen was considered of reduced intensity.

Neutrophil recovery was defined as the first of 3 consecutive days when the absolute neutrophil count was $0.5 \times 10^9/L$ or higher, irrespective of donor hematopoiesis. Platelet recovery was defined as the first of 7 consecutive days when platelet count reached $20 \times 10^9/L$ or higher, independent of platelet transfusions and irrespective of the degree of donor hematopoiesis. Full-donor chimerism was defined as at least 95% leucocytes of donor origin in peripheral blood or marrow samples, measured by different techniques according to transplantation centers. Autologous reconstitution was defined as at least 95% leucocytes of recipient origin, and there was mixed chimerism when greater than 5% but less than 95% leucocytes were of donor origin. Acute GVHD was diagnosed and graded according to standard criteria.⁹ Chronic GVHD was also diagnosed according to standard criteria.¹⁰ Only patients with sustained donor engraftment surviving more than 100 days after CBT were considered at risk of developing chronic GVHD. Nonrelapse mortality (NRM) was defined as any death not related to relapse. Relapse was defined on the basis of morphologic recurrence of original disease. Response to donor lymphocyte infusion (DLI) or second transplantation was defined as no relapse or death occurring after treatment until the date of last follow-up. Overall survival (OS) was calculated from transplantation to death from any cause, and DFS was defined as the time from transplantation to either relapse or death, whichever occurred first.

Statistical analysis

The duration of follow-up was the time to last assessment for survivors. For each continuous variable, the study population was initially split into quartiles and in 2 groups by the median. The median value was found to be the best cutoff for analysis of all outcomes with one exception: for analysis of OS, the years of transplantation were best split into 3 categories (< 1997, 1997-2003, and ≥ 2004). Variables considered in risk factor analysis for

neutrophil recovery, relapse, DFS, and OS were year of transplantation (with < 1997 vs ≥ 1997 and < 2004 vs ≥ 2004 for OS and the median year of transplantation of 2000 as a cutoff for all other outcomes), recipient age (with the median age of 5 years as a cutoff), sex (female vs male), cytomegalovirus serologic status (negative vs positive), previous autologous transplantation (no vs yes), disease status category according to International Bone Marrow Transplant Registry criteria (early, intermediate, advanced), ABO match (match, minor incompatibility, major incompatibility), sex match (match vs mismatched), infused cell dose in total nucleated cells (TNCs) per kilogram (with the median infused TNCs of $4.1 \times 10^7/kg$ as a cutoff), use of TBI vs busulfan in myeloablative conditioning, use of MTX for GVHD prophylaxis (no vs yes). A subgroup risk factor analysis for patients with AL was performed with the use of the same methods, variables, and statistics except that the remission status (CR1, CR2, CR3, and refractory disease, as well as state of CR vs no remission) was used instead of the Center for International Blood and Marrow Transplant Research disease status categories. An association between categorical variables was tested by the chi-square test. The confidence intervals (CIs) of neutrophil recovery, platelet recovery, and chronic GVHD were calculated with the use of death from any cause and second transplantations as competing risks, and the CIs of acute GVHD was calculated only with the use of death as a competing risk. Second transplantations, as well as death in remission and relapse, were competing risks for calculating CI of relapse and NRM, respectively. Univariate analysis for these outcomes was done with the use of the Fine and Gray test. Probabilities of DFS and OS were calculated with the use of the Kaplan-Meier estimate, and the log-rank test was used for univariate comparisons. Multivariate analyses were performed with Cox proportional hazards regression model for DFS and OS, and Fine and Gray proportional hazards regression model was used for subdistribution of other outcomes.¹¹ Variables that reached a *P* value of .20 after univariate analysis were included in the initial models, and variables were eliminated one at a time in a stepwise fashion to only keep variables that reached a *P* value of .05 or less into the final models. All *P* values were 2-sided, with a type I error rate fixed at 0.05. Statistical analyses were performed with SPSS Version 18 (SPSS Inc) and S-Plus Version 6.1 (MathSoft) software.

Results

Patient, disease, graft, and transplantation characteristics

Patient and disease characteristics are described in Table 1. All patients were children except 3, aged 18, 19, and 31 years, respectively. The majority (74%) of patients had AL. Intermediate disease patients constituted the largest risk group. For the 109 patients with AL, there were 4 cases of secondary AL. Among the 82 patients with acute lymphoblastic leukemia (ALL), 54 had available cytogenetics; 7 patients had Philadelphia chromosome ALL. Among the 20 patients with acute myeloid leukemia, 12 had available cytogenetics, including 6 with high-risk anomalies (namely complex karyotype or monosomy 7).

Graft and transplantation characteristics are detailed in Table 2. All CB donors were siblings except one who was a patient's child. The CB unit was transplanted within a median of 3.6 months after birth of the CB donor. The patient's diagnosis antedated the birth of the CB donor by a median of 12 months (0-101 months). There were 60 cases in which this difference was 9 months or less, indicating that the patient's mother was pregnant with the CB donor at the time of the patient's diagnosis. In 82 cases, this difference was more than 9 months, meaning that the CB donor's conception took place after the patient's initial diagnosis. All CB units, except for one that was infused as a fresh product, were cryopreserved at the local hospital cell therapy laboratory or at the nearest public cord blood bank.

The number of CD34⁺ cells collected or infused was measured in only a minority of cases (data not shown). Nearly all patients

Table 1. Patient and disease characteristics

Characteristic	Value	n
Male sex, n (%)	90 (61)	147
Median age, y (range)	5.0 (1.0-31.6)	147
Median weight, kg (range)	18.4 (8-69)	146
Previous autologous transplantation, n (%)	11 (7.6)	145
Positive CMV serology, n (%)	65 (46)	141
Diagnosis		147
Acute leukemia	109 (74)	
ALL, n	82	
AML, n	20	
Biphenotypic, n	6	
Undifferentiated, n	1	
Myelodysplastic syndrome, n (%)	17 (12)	
JMML, n	10	
Other MDS, n	3	
Unspecified MDS, n	4	
Chronic myeloid leukemia, n (%)	12 (8)	
Lymphoproliferative disorder, n (%)	3 (2)	
Anaplastic large cell lymphoma, n	1	
Burkitt lymphoma, n	2	
Solid tumor, n (%)	6 (4)	
Neuroblastoma, n	5	
Ewing sarcoma, n	1	
Disease status		147
Early, n (%)	40 (27)	
Intermediate, n (%)	70 (48)	
Advanced, n (%)	37 (25)	
Median time from diagnosis to RCBT, mo (range)	17.0 (0.8-117.8)	147
Early	8.9 (0.8-82.5)	
Intermediate	36.0 (5.7-117.8)	
Advanced	12.2 (1.4-52.2)	
Remission status in patients with AL		109
First CR, n (%)	31 (28)	
Second CR, n (%)	51 (47)	
Third or subsequent CR, n (%)	13 (12)	
Refractory disease, n (%)	14 (13)	
Median time from diagnosis to RCBT in patients with AL patients, mo (range)	22.2 (0.8-117.8)	109
First CR	7.8 (0.8-23.2)	
Second CR	33.8 (5.7-88.5)	
Third or subsequent CR	48.5 (16.1-117.8)	
Refractory disease	15.0 (6.0-45.2)	
Median time from last CR to RCBT in patients with AL, mo (range)	3.8 (0.2-25.6)	82
First CR	6.8 (0.7-15.5)	
Second CR	3.2 (0.4-25.6)	
Third or subsequent CR	2.2 (0.2-12.0)	
Refractory disease	NA	
Median length of first CR in patients with AL beyond first CR, mo (range)	26.3 (2.2-80.4)	59

CMV indicates cytomegalovirus; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic syndrome; RCBT, related cord blood transplantation; AL, acute leukemia; and CR, complete remission.

(97%) received a myeloablative conditioning regimen with half based on TBI and half based on busulfan (one patient received treosulfan at a dose of 12 g/m²). Eleven patients (8%) received antithymocyte globulin. GVHD prophylaxis was based on a calcineurin inhibitor (cyclosporine or tacrolimus) for nearly all patients; 15% of patients received MTX in addition to cyclosporine.

Hematopoietic reconstitution

One hundred thirty-three patients reached a neutrophil count of at least $0.5 \times 10^9/L$, within a median time of 24 days (range,

Table 2. Donor and transplantation characteristics

Characteristic	Value	n
Median age difference between patient and CB donor, y (range)	4.1 (0.9-30.7)	142
Median storage time of the CB unit, mo (range)	3.6 (0-66.5)	142
Early disease	3.0 (1.0-53.6)	
Intermediate disease	5.7 (0-66.5)	
Advanced disease	2.8 (0.8-10.4)	
Median total nucleated cells at collection, $\times 10^8$ (range)	10.8 (1.3-36.3)	127
Median total nucleated cells/kg at collection, $\times 10^7/kg$ (range)	5.1 (1.0-34.6)	126
Median total nucleated cells/kg at infusion, $\times 10^7/kg$ (range)	4.1 (0.7-34.6)	141
ABO compatibility		143
Compatible, n (%)	97 (68%)	
Minor incompatibility, n (%)	16 (11%)	
Major incompatibility, n (%)	30 (21%)	
Sex matching (CB/patient)		146
Male/male or female/female, n (%)	80 (55%)	
Male/female, n (%)	34 (23%)	
Female/male, n (%)	32 (22%)	
Conditioning regimen		147
Reduced intensity, n (%)	4 (3%)	
Myeloablative, n (%)	143 (97%)	
With TBI	72	
With busulfan (or treosulfan)*	71	
Antithymocyte globulin, n (%)	11 (8%)	
Use of growth factors after RCBT		125
None, n (%)	39 (31%)	
G-CSF, n (%)	78 (62%)	
GM-CSF, n (%)	5 (4%)	
G-CSF and GM-CSF, n (%)	1 (1%)	
G-CSF and EPO, n (%)	2 (2%)	
Median day of onset of growth factors after RCBT (range)	Day (day 0-37)	79
GVHD prophylaxis		147
None, n (%)	3 (2%)	
Steroids alone, n (%)	2 (1%)	
Calcineurin inhibitor-based, n (%)	142 (97%)	
CsA alone, n	104	
CsA + MMF, n	3	
CsA + MTX, n	20	
CsA + MTX + steroids, n	1	
CsA + steroids, n	13	
Tacrolimus + steroids, n	1	

CB indicates cord blood; TBI, total body irradiation; CSF, colony-stimulating factor; G, granulocyte; GM, granulocyte macrophage; EPO, erythropoietin; CsA, cyclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate; and RCBT, related cord blood transplantation.

*Only 1 patient received treosulfan at a dose of 12 g/m².

4-73 days). The CI of neutrophil recovery at day +60 was 90% plus or minus 3%. Of those 133 patients, chimerism studies were performed and reported in 108 patients: 93 patients (86%) had full donor chimerism, 11 patients (10%) had mixed chimerism, and 4 patients (4%) had autologous reconstitution. Of the 18 patients who did not achieve neutrophil recovery (n = 14) or who had autologous reconstitution (n = 4), only 2 were alive at last follow-up: one at 13 years of follow-up, after receiving an autologous stem cell transplant on day +43, and the other at 2.5 years of follow-up after receiving chemotherapy. The other 16 patients died early after transplantation, at a median of 30 days (range, 5-514 days), including one patient who died on day +119 after receiving a second transplant with bone marrow from the same donor on day +31. Of the 12 patients with mixed chimerism,

Table 3. Univariate analysis for neutrophil recovery, relapse and disease-free survival

Risk factor	n	Neutrophil recovery			Relapse			DFS		
		No. of events	CI at day 60, %	P	No. of events	CI at 5 y, %	P	No. of events	Prob. at 5 y, %	P
Year of transplantation										
Before 2000	70	60	84 ± 4	.07	38	54 ± 6	.07	46	34 ± 6	.01
2000 or later	77	73	95 ± 3		29	39 ± 6		34	54 ± 6	
Patient sex										
Female	57	52	89 ± 5	.96	22	40 ± 7	.19	26	53 ± 7	.11
Male	90	81	90 ± 3		45	51 ± 5		54	39 ± 5	
Patient age										
Younger than 5 y	73	71	97 ± 2	.01	36	51 ± 6	.26	39	45 ± 6	.87
5 y or older	74	62	82 ± 5		31	43 ± 6		41	43 ± 6	
Disease status at RCBT										
Early-intermediate	110	101	91 ± 3	.78	46	43 ± 5	.03	57	47 ± 5	.10
Advanced	37	32	86 ± 6		21	57 ± 8		23	37 ± 8	
Infused TNC										
Less than 4.1 × 10 ⁷ /kg	72	62	85 ± 4	.001	34	49 ± 6	.71	44	37 ± 6	.11
4.1 × 10 ⁷ /kg or greater	69	65	94 ± 3		30	45 ± 6		33	51 ± 6	
Type of myeloablative conditioning										
Busulfan-based	72	66	92 ± 3	.33	37	54 ± 6	.08	41	40 ± 6	.44
TBI-based	71	63	88 ± 4		28	39 ± 6		37	48 ± 6	
Use of MTX										
No	126	117	92 ± 2	.009	55	45 ± 5	.15	65	47 ± 5	.02
Yes	21	16	76 ± 10		12	57 ± 11		15	27 ± 10	

DFS indicates disease-free survival; OS, overall survival; CI, cumulative incidence; Prob, probability; RCBT, related cord blood transplantation; TNC, total nucleated cells; TBI, total body irradiation; and MTX, methotrexate.

Other factors analyzed but found to have no significant association with any of the outcomes in the whole cohort are patient's cytomegalovirus status, previous autologous transplantation, ABO matching, and sex matching.

8 are alive, including 1 patient at 2.2 years of follow-up after receiving a haplo-identical stem cell transplant from his father on day +72 for secondary graft failure.

We found that the median infused TNC dose (4.1 × 10⁷/kg) was the best cutoff to separate results of neutrophil engraftment because lower doses failed to stratify results: of 31 patients who had an infused graft with less than 2.7 × 10⁷/kg TNCs (lower quartile), 5 did not achieve neutrophil recovery, and their CI of neutrophil recovery was 84% plus or minus 7%. Three of 18 patients who received an infused TNC dose less than 2.0 × 10⁷/kg, and 1 of 2 patients who received less than 1.0 × 10⁷/kg did not achieve neutrophil recovery. All 36 patients with a median infused TNC dose of at least 6.6 × 10⁷/kg (upper quartile) achieved neutrophil recovery. In univariate analysis (Table 3), CI of neutrophil recovery was higher in patients younger than 5 years (*P* = .01), in patients receiving an infused TNC dose of at least 4.1 × 10⁷/kg (Figure 1A; *P* = .001), and in patients not receiving MTX (Figure 1B; *P* = .009). After multivariate analysis (Table 4), 2 factors remained independently associated with neutrophil recovery: an infused TNC dose of at least 4.1 × 10⁷/kg (*P* = .003) and the absence of MTX in the GVHD prophylaxis regimen (*P* < .001). The use of growth factors did not have a significant influence on neutrophil recovery (data not shown).

One hundred twenty-two patients reached a platelet count of at least 20 × 10⁹/L at a median of 38 days (range, 11-253 days). The CI of platelet recovery at day +180 was 84% plus or minus 3%.

Graft-versus-host disease

Grade II to IV acute GVHD CI at day +100 was 12% plus or minus 3%, with a median of 12.5 days to the onset of acute GVHD after CBT (range, 8-25 days). The severity of acute GVHD was low with 34 patients having grade I, 16 with grade II, 1 with grade III, and none with grade IV. Fourteen patients developed chronic GVHD, only 2 of extensive grade, after a median of 236 days after CBT




Figure 1. Neutrophil recovery. (A) Cumulative incidence of neutrophil recovery according to infused TNC dose in the whole cohort (n = 147). (B) Cumulative incidence of neutrophil recovery according to use of methotrexate (MTX) in the whole cohort (n = 147).

Table 4. Multivariate analysis for neutrophil recovery, relapse and disease-free survival

Factor	HR	95% CI	P	Favorable factor
Neutrophil recovery				
Infused TNC				
4.1 × 10 ⁷ /kg or greater	1.72	1.20-2.45	.003	Higher infused TNC
Less than 4.1 × 10 ⁷ /kg	1.00			
Use of MTX				
Yes	0.48	0.31-0.73	< .001	Lack of MTX
No	1.00			
Relapse				
Disease status				
Advanced	1.81	1.04-3.15	.04	Early-intermediate disease
Early-intermediate	1.00			
Disease-free survival				
Year of transplantation				
2000 and later	0.50	0.31-0.79	.003	Transplant year ≥ 2000
Before 2000	1.00			
Disease status				
Advanced	1.74	1.01-2.97	.04	Early-intermediate disease
Early-intermediate	1.00			
Infused TNC				
4.1 × 10 ⁷ /kg or greater	0.56	0.34-0.91	.02	Higher infused TNC
Less than 4.1 × 10 ⁷ /kg	1.00			

HR indicates hazard ratio; CI, confidence interval; TNC, total nucleated cell dose; MTX, methotrexate

Variables included in the multivariate analysis models for all cases were (1) for neutrophil recovery: year of transplantation (before 2000 vs 2000 or later), patient's age (<5 vs ≥5 years), disease status (early-intermediate vs advanced), infused TNC (<4.1 vs ≥4.1 times 10⁷/kg), and use of MTX (no vs yes); (2) for relapse: year of transplantation (before 2000 vs 2000 or later), disease status (early-intermediate vs advanced), and use of TBI (no vs yes); and (3) for disease-free survival: year of transplantation (before 2000 vs 2000 or later), sex (female vs male), disease status (early-intermediate vs advanced), infused cell dose (<4.1 vs ≥4.1 × 10⁷/kg), and use of MTX (no vs yes).

(range, 85-473 days). CI of chronic GVHD at 2 years was 10% plus or minus 2%. Given the low incidence of both acute and chronic GVHD, a risk factor analysis for these outcomes was not performed.

Nonrelapse causes of death and nonrelapse mortality

Fifteen patients (23%) died of transplantation-related causes, including 6 patients from infection and 2 patients after second transplantation with bone marrow from the CB donor, performed for relapse of leukemia (one with CML in first chronic phase dying of hemorrhage and the other with ALL in second CR dying of bronchiolitis obliterans). Nonrelapse deaths after initial RCBT (n = 13, as reported in Table 5) occurred early, at a median of 25 days (range, 5 days to 2.6 years). CI of NRM at 5 years was 9% plus or minus 2%. A risk factor analysis was not performed, given the low number of events.

Relapse

Relapse occurred in 67 patients within a median time of 6.8 months (range, 11 days to 3.9 years) after RCBT. Overall, CIs of relapse were 35% plus or minus 4% at 1 year, 43% plus or minus 4% at 2 years, and 47% plus or minus 4% at 5 years. Early or intermediate disease was the only factor found to significantly decrease the 5-year CIs of relapse in both univariate (Table 3; P = .03) and multivariate analysis (Table 4; P = .04).

Among the 109 patients with AL, CIs of relapse were 35% plus or minus 5% at 1 year, 43% plus or minus 5% at 2 years, and 44% plus or minus 5% at 5 years. There were 48 relapses: 10 of 31 patients in first CR (CI at 5 years, 33% ± 9%), 23 of 51 patients in second CR (CI at 5 years, 46% ± 7%), 5 of 13 patients in third or subsequent CR (CI at 5 years, 39% ± 14%), and 9 of 14 patients with refractory disease (CI at 5 years, 64% ± 14%; P = .04). Univariate analysis showed that a lower relapse incidence at 5 years was seen in patients given RCBT in remission compared with patients not in remission (41% ± 5% vs 64% ± 14%; P = .007) and in patients receiving a myeloablative conditioning regimen with TBI compared with busulfan (35% ± 6% vs 55% ± 8%; P = .03). No statistical difference was observed in relapse incidence between ALL and acute myeloid leukemia cases. After multivariate analysis adjusted for patient's age and sex, a state of CR at time of transplantation (hazard ratio, 0.40; 95% CI, 0.17-0.96; P = .04) and the use of TBI (hazard ratio, 0.52; 95% CI,

Table 5. Nonrelapse deaths, relapse, response to DLI, and second transplantations according to diagnosis and disease status at RCBT

Remission or phase/disease status at RCBT	N	Nonrelapse deaths, n	Relapse, n	Median time from RCBT to relapse, mo (range)	DLI			Second transplantations*		
					N	Response, n†	Median duration of response, y (range)†	N	Response, n†	Median duration of response, y (range)†
Acute leukemia										
First CR/early	31	3	10	8.0 (1.0-27.8)	1	1	15.7	4	4	4.0 (1.1-8.7)
Second CR/int	51	4	23	8.7 (1.5-17.5)	4	1	1.8	7‡	2	5.4 (2.5-8.3)
Third or more CR/int	13	4	5	4.6 (1.0-13.5)	0	NA	NA	2	0	NA
Refractory/advanced	14	2	9	3.2 (0.4-7.9)	1	0	NA	0	NA	NA
MDS Advanced	17	0	8	3.7 (0.6-26.0)	1	0	NA	5‡	2	5.0 (3.0-6.9)
CML										
First chronic phase/early	9	0	6	11.9 (4.9-43.7)	2	1	13.4	2	0	NA
Accelerated phase/int	3	0	2	28.5 (9.9-47.1)	2	1	5.3	1‡	1	9.2
Lymphoma, second or more CR/int	3	0	0	NA	0	NA	NA	0	NA	NA
Solid tumors, advanced	6	0	4	7.5 (5.6-9.7)	0	NA	NA	0	NA	NA
Total	147	13	67	6.8 (0.4-47.1)	11	4 (36%)	9.2 (1.8-15.7)	21	9 (43%)	6.0 (1.1-9.2)

RCBT indicates related cord blood transplantation; DLI, donor lymphocyte infusion; CR, complete remission; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; int: intermediate.

*Donor types: 15 with bone marrow (n = 14) or peripheral blood stem cells (n = 1) from the same donor; 1 haploidentical stem cell transplantation from the mother (acute myeloid leukemia in first CR), 3 unrelated bone marrow (1 acute lymphoblastic leukemia [ALL] in second CR, 1 MDS, 1 CML in accelerated phase), and 2 unspecified donor types (1 ALL in first CR, 1 ALL in third or more CR).

†Response to DLI or second transplantation was defined as no relapse or death occurring after treatment until the date of last follow-up.

‡A total of 3 patients (one with acute leukemia, one with MDS, and one with CML) received a second transplantation after failure of DLI.




Figure 2. Disease-free survival according to year of transplantation in the whole cohort (n = 147).

0.29-0.94; $P = .03$) remained independently associated with a lower relapse incidence in patients with AL.

Treatment of relapse

Treatment for relapse was reported for 59 of 67 relapsing patients. Ten patients (17%) received supportive care, all dying within a median of 45 days (range, 3 days to 24 months) after relapse. Chemotherapy was administered to 33 patients, including 20 patients (34%) for whom this was the only treatment given for relapse. Of those 20 patients, only 2 are alive at last follow-up (one with ALL in first CR and one with CML in first chronic phase given chemotherapy and subsequently imatinib mesylate), the other 18 patients died at a median of 12 months (range, 6 days to 33 months) after relapse. Treatment of relapse was not reported for 8 patients: 7 of them died at a median of 2.0 months (range, 0.6-8.3 months) after relapse and 1 died at 43.6 months after relapse. Eleven patients received at least one DLI from the initial CB donor, administered at a median of 11.0 months (range, 3.6 months to 4.5 years) after CBT. Second transplantation was performed in 21 relapsing patients (including 3 patients who also received DLI) at a median of 12.4 months after CBT (range, 4.8-38.0 months). Fifteen second transplantations were done with bone marrow (n = 14) or peripheral blood stem cells (n = 1) from the same RCB transplant donor; 1 patient was given a haplo-identical stem cell transplant from the mother, and 3 patients underwent an unrelated BMT. In 2 cases, the second transplant donor was not specified. Details on the response to DLI and second transplantations according to diagnosis and disease status are given in Table 5.

Disease-free survival

The probability of DFS was 56% plus or minus 4% at 1 year, 49% plus or minus 4% at 2 years, and 44% plus or minus 4% at 5 years. DFS was found to improve over time (Figure 2; $P = .04$). Indeed, there was a strong association between the use of MTX and the year of transplantation: 29% patients received MTX before 1997, 26% from 1997 to 1999, 6% from 2000 to 2003, and none since 2004 ($P < .001$). In the AL population, the proportion of patients who received a transplant in first or second CR increased overtime: 54%




Figure 3. Disease-free survival in acute leukemia patients according to remission status (n = 109).

before 1997, 84% from 1997 to 1999, 72% from 2000 to 2003, and 90% since 2004 ($P = .01$). Table 3 shows the univariate analysis for DFS. In multivariate analysis, transplantation year of 2000 or later ($P = .003$), early or intermediate disease ($P = .04$), and infused TNCs of at least $4.1 \times 10^7/\text{kg}$ ($P = .02$) were found to predict better DFS (Table 4).

For the subgroup of patients with AL, 5-year DFS was influenced by remission status, because it was 57% plus or minus 9%, 46% plus or minus 7%, 31% plus or minus 13%, and 21% plus or minus 11%, respectively, for patients who received a transplant in first CR, second CR, third CR, and in refractory disease, (Figure 3; $P = .006$). The 5-year DFS of patients who did or did not receive MTX was 24% plus or minus 10% and 48% plus or minus 5%, respectively ($P = .007$). After multivariate analysis adjusted for year of transplantation, patient's sex and use of TBI, only a state of CR (hazard ratio, 0.41; 95% CI, 0.21-0.79; $P = .008$), and the lack of MTX in GVHD prophylaxis regimen (hazard ratio, 0.48; 95% CI, 0.26-0.89; $P = .02$) remained significantly associated with superior DFS.

Overall survival

The probability of OS was 75% plus or minus 4% at 1 year, 63% plus or minus 4% at 2 years, and 55% plus or minus 4% at 5 years. Similarly to DFS, OS was also found to improve over time with an OS at 5 years of 34% plus or minus 8% before 1997, 55% plus or minus 6% from 1997 to 2003, and 76% plus or minus 7% since 2004 ($P = .003$). Patients not receiving MTX had improved survival compared with patients who received this drug for GVHD prophylaxis ($58\% \pm 5\%$ vs $33\% \pm 10\%$; $P = .006$). Patients with early disease had a better survival ($74\% \pm 7\%$) than patients with intermediate ($51\% \pm 6\%$) or advanced disease ($42\% \pm 8\%$; $P = .02$). After multivariate analysis adjusted for infused cell dose, year of transplantation of at least 1997 (hazard ratio, 0.54; 95% CI, 0.32-0.91; $P = .02$), early disease (hazard ratio, 0.44; 95% CI, 0.23-0.87; $P = .02$), and absence of methotrexate (hazard ratio, 0.54; 95% CI, 0.29-0.99; $P = .05$) were found to be independently associated with better OS. In patients with AL, OS was 71% plus or minus 4% at 1 year, 61% plus or minus 5% at 2 years, and 51% plus or minus 5% at 5 years.

Discussion

In this registry-based study, we identified 3 main factors that influenced outcomes after HLA-identical RCBT in malignancies: cell dose, use of MTX for GVHD prophylaxis, and disease status at transplantation. A higher infused TNC dose, using the median ($\geq 4.1 \times 10^7/\text{kg}$) to separate groups, was associated with better neutrophil recovery. Lower TNC dose cutoffs did not stratify neutrophil engraftment rates any further. This is the first report to show an influence of cell dose on neutrophil recovery in the HLA-identical RCBT setting, and this finding may thus warrant confirmation in a larger cohort of patients. Indeed, cell dose has been identified as a predictor of engraftment in the unrelated HLA-mismatched CBT setting^{5,12-15} and is therefore considered to be a major criterion for CB unit selection, together with HLA matching. Three of 18 patients who received less than $2.0 \times 10^7/\text{kg}$ TNCs in this study failed to engraft. An option when collected cell dose is low in the related setting could be to add bone marrow cells from the same sibling donor, although, to our knowledge, there are no published reports of this practice.

As previously reported in patients with hemoglobinopathies³ and in a more limited cohort of patients with malignant diseases undergoing RCBT,⁴ the use of MTX for GVHD prophylaxis was shown to have a negative effect on neutrophil recovery. MTX effectively prevents GVHD; however, in view of the low incidence of this complication after CBT (particularly after HLA-identical RCBT) and of the negative effect of the drug on neutrophil recovery and on the graft-versus-tumor effect, the use of MTX appears detrimental after RCBT. Indeed, inclusion of MTX in GVHD prophylaxis has considerably decreased over time, because none of the patients included in this analysis and undergoing transplantation after 2002 received this drug. Finally, patients undergoing transplantation with early disease had better DFS, particularly in the subgroup of patients with AL whereby remission status was strongly associated with DFS. This influence of disease status on relapse, DFS, and OS has been well described in previous reports of related and unrelated CBT for malignancies.^{5,7,15,16} We did not observe an influence of the recipient's cytomegalovirus serologic status, as well as of the recipient's age on the different outcomes after adjusting for other factors.

Survival rates have improved over time. This can be explained by the decreasing use of MTX, as well as by better patient selection over time, particularly for AL cases whereby the proportion of patients undergoing transplantation in first and second remission was higher in more recent years. Other factors not evaluated in this study that may have also played a role in this improvement are the growing experience with CBT and better treatment of infections and other transplantation-related complications.

As previously reported in RCBT,²⁻⁴ we found a low incidence of NRM, as well as low incidence and severity of acute and chronic GVHD. Indeed, incidences of NRM and GVHD increase with increasing HLA disparities between CB donor and recipient, both in the related and the unrelated CBT setting.^{5,7,17} Given that the CB donors in this cohort were all HLA-identical relatives, this explains these results.

Relapse incidence was relatively high in the present study, being 43% at 2 years and 47% at 5 years. A relapse rate of 20% at 2 years was reported in the Cord Blood Transplantation study¹⁷ that included 191 children with hematologic malignancies undergoing unrelated CBT. The difference in relapse rates between related and unrelated CBT probably reflects a stronger graft-versus-tumor

effect after unrelated CBT, given that in the unrelated setting most CB units are HLA-mismatched. However, in the Cord Blood Transplantation study, a high NRM rate compensated for the low relapse rate and resulted in an OS of 50% at 2 years,¹⁷ similar to what is seen in the present study.

A comparative study between HLA-identical sibling CBT and BMT previously showed no difference in OS despite an initial lower engraftment rate in the CBT group.² Incidences of acute and chronic GVHD were lower in the CBT group. Neither relapse nor DFS were compared because follow-up was short. In the present study, we found a probability of DFS of 44% at 5 years (53% for patients receiving transplants since 2000) in patients with AL and a strong association with remission status. In the few studies of related HLA-identical BMT for AL in pediatric patients, DFS at 5 years varied from 40% to 60%.^{18,19} One advantage of a related donor is the availability of this donor for a second transplantation or DLI if required. In fact, in our study, 25 of the 59 relapsing patients for whom treatment of relapse was reported received either DLI or BMT from the initial CB donor with a response rate of 36% and 40% for DLI and BMT, respectively.

Until recently, and still today in most countries, RCBTs have relied on collaboration between highly motivated families, obstetricians, midwives, and transplantation center hematologists. In the past years, several directed sibling CB banks have been established in different countries.²⁰⁻²³ Experience has, however, shown that the utilization rate of stored related CB units is low, particularly in the setting of malignant diseases (Ferry et al, unpublished data from 2 such banks in Paris, 2009). Whether directed sibling CB banks should be implemented on a large scale for clinical use in patients with malignancies would require discussions with considerations for the indications for banking, costs, and effectiveness.

All CB donors were younger siblings (and one patient's offspring), and the patient's diagnosis antedated the CB donor's birth. In 60 cases, the mother was pregnant at the time of diagnosis, and the CB unit was stored or used immediately after birth. Interestingly, in 82 cases, the CB donor was conceived after diagnosis. Whether this was done with the aim of conceiving a "saviour sibling" or simply a reflection of the fact that a significant proportion of parents of a young child with a malignancy may still be planning to expand their family is unknown. Preimplantation genetic diagnosis with HLA-typing has been used to treat patients with nonmalignant inherited disorders,²⁴⁻²⁶ but, to our knowledge; there is no report of this technique being applied in the setting of a malignant disorder.

In summary, cell dose, use of MTX, and disease status are the main factors found to influence outcomes after HLA-identical RCBT. The good outcomes presented here support banking and use of HLA-identical sibling CB. If the mother of a child with a hematologic malignancy who may require transplantation becomes pregnant, all efforts should be made to cryopreserve the CB of the newborn sibling.

Authorship

Contribution: A.-L.H., N.K., P.T., E.G., and V.R. designed the study; A.-L.H., N.K., P.T., W.C., and I.I. contacted centers and collected data; C.M.S.B., F.L., K.T., A.L., J.-P.J., C.M., Y.B., C.D.d.H., and S.K.N. submitted at least 4 patients/center for the study; A.-L.H., I.I., and V.R. analyzed data; A.-L.H. and V.R. wrote the paper; and A.-L.H., N.K., C.M.S.B., P.T., F.L., K.T., A.L.,

J.-P.J., C.M., Y.B., C.D.d.H., C.P., W.C., S.K.N., I.I., E.G., and V.R. edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

A complete list of Eurocord-EBMT members appears as an online data supplement to this article (available on the *Blood* Web

site; see the Supplemental Materials link at the top of the online article).

Correspondence: Andrée-Laure Herr, Eurocord, Hôpital Saint-Louis, 1 ave Claude Vellefaux, Quadrilatère porte 5, 75475 Paris cedex 10, France; e-mail: andree-laure.herr-bellon@sls.aphp.fr.

References

- Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med*. 1989;321(17):1174-1178.
- Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. *N Engl J Med*. 2000;342(25):1846-1854.
- Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. *Blood*. 2003;101(6):2137-2143.
- Gluckman E, Rocha V, Boyer-Chamard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. *N Engl J Med*. 1997;337(6):373-381.
- Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. *Blood*. 1999;93(11):3662-3671.
- Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. *Lancet*. 1995;346(8969):214-219.
- Teira P, Rocha V, Kabbara N, et al. Risk factors analysis of outcomes of related cord blood transplantation in children with hematological malignancies. *Bone Marrow Transplant*. 2008;39(suppl 1):S10-S11.
- Szyldo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. *J Clin Oncol*. 1997;15(5):1767-1777.
- Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. *Transplantation*. 1974;18(4):295-304.
- Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. *Am J Med*. 1980;69(2):204-217.
- Fine JP, Gray RJ. A proportional hazards model for substitution of a competing risk. *J Am Stat Assoc*. 1999;94:496-509.
- Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. *N Engl J Med*. 1998;339(22):1565-1577.
- Gluckman E. Hematopoietic stem-cell transplants using umbilical-cord blood. *N Engl J Med*. 2001;344(24):1860-1861.
- Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. *Blood*. 2002;100(5):1611-1618.
- Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. *Blood*. 2003;102(13):4290-4297.
- Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. *Lancet*. 2007;369(9577):1947-1954.
- Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. *Blood*. 2008;112(10):4318-4327.
- Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. *Blood*. 2000;95(5):1572-1579.
- Saarinén-Pihkala UM, Gustafsson G, Ringden O, et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. *J Clin Oncol*. 2001;19(14):3406-3414.
- Smythe J, Armitage S, McDonald D, et al. Directed sibling cord blood banking for transplantation: the 10-year experience in the national blood service in England. *Stem Cells*. 2007;25(8):2087-2093.
- Reed W, Smith R, Dekovic F, et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. *Blood*. 2003;101(1):351-357.
- Goussetis E, Petrakou E, Theodosaki M, et al. Directed sibling donor cord blood banking for children with beta-thalassemia major in Greece: usage rate and outcome of transplantation for HLA-matched units. *Blood Cells Mol Dis*. 2010;44(2):107-110.
- Screnci M, Murgi E, Carmini D, et al. Related cord blood banking for hematopoietic stem cell transplantation. *Transfus Med*. 2010;20(3):185-190.
- Verlinsky Y, Rechitsky S, Schoolcraft W, Strom C, Kuliev A. Preimplantation diagnosis for Fanconi anemia combined with HLA matching. *JAMA*. 2001;285(24):3130-3133.
- Grewal SS, Kahn JP, MacMillan ML, Ramsay NK, Wagner JE. Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. *Blood*. 2004;103(3):1147-1151.
- Goussetis E, Konialis CP, Peristeri I, et al. Successful hematopoietic stem cell transplantation in two children with X-linked chronic granulomatous disease from their unaffected HLA-identical siblings selected using pre-implantation genetic diagnosis combined with HLA-typing. *Biol Blood Marrow Transplant*. 2010;16(3):344-349.